ClinicalTrials.gov
ClinicalTrials.gov Menu

Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00186576
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : October 14, 2010
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by:
Stanford University

September 14, 2005
September 16, 2005
October 14, 2010
December 2001
March 2004   (Final data collection date for primary outcome measure)
Efficacy of transplant [ Time Frame: 1 year ]
Efficacy
Complete list of historical versions of study NCT00186576 on ClinicalTrials.gov Archive Site
safety profile of nonmyeloablative transplant, graft versus host disease, graft rejection, non-relapse mortality, use of donor lymphocyte infusion [ Time Frame: 1 year ]
safety profile of nonmyeloablative transplant, GVHD, graft rejection, non-relapse mortality, use of DLI
Not Provided
Not Provided
 
Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)
To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)
Interventional
Not Applicable
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Myelodysplastic Syndromes
  • Myeloproliferative Disorders
  • Blood and Marrow Transplant (BMT)
  • Myelodysplastic Syndromes (MDS)
  • Myeloproliferative Disorders (MPD)
Procedure: nonmyeloablative allogeneic hematopoietic cell transplant
Not Provided
Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, Maris MB, Agura ED, Chauncey TR, Wong RM, Forman SJ, Petersen FB, Wade JC, Epner E, Bruno B, Bethge WA, Curtin PT, Maloney DG, Blume KG, Storb RF. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant. 2008 Feb;14(2):246-55. doi: 10.1016/j.bbmt.2007.11.012.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
Same as current
July 2010
March 2004   (Final data collection date for primary outcome measure)

Inclusion Criteria:- Myelodysplastic Syndromes

  • Myeloproliferative Disorders
  • HLA matched donor available

Exclusion Criteria:- organ dysfunction

  • HIV positive
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00186576
BMT128
75826
BMT128
Not Provided
Not Provided
Not Provided
Ginna Laport, Stanford University School of Medicine
Stanford University
National Institutes of Health (NIH)
Principal Investigator: Ginna Laport Stanford University
Stanford University
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP